GSK Advair Diskus Clears FDA For COPD; Bone Density Study In Phase IV
Executive Summary
GlaxoSmithKline will study Advair Diskus 250/50 for its effects on bone mineral density as one Phase IV commitment following FDA's Nov. 17 supplemental approval for chronic obstructive pulmonary disease associated with bronchitis
You may also be interested in...
Pfizer/Boehringer Spiriva Clears FDA For COPD; Launch Set For Summer
Pfizer/Boehringer Ingelheim's marketing plan for Spiriva will emphasize the drug's long-term efficacy compared to other COPD therapies
Pfizer/Boehringer Spiriva Clears FDA For COPD; Launch Set For Summer
Pfizer/Boehringer Ingelheim's marketing plan for Spiriva will emphasize the drug's long-term efficacy compared to other COPD therapies
GSK Flovent/Advair Diskus Needs More COPD Data; Serevent Cleared For COPD
FDA is seeking additional efficacy data on GlaxoSmithKline's Flovent Diskus and Advair Diskus for chronic obstructive pulmonary disease before approving the products for the supplementary indication